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KETAMINE. Success or failure with the use of
ketamine depends largely on three factors :
1. Awareness that ketamine is different from
traditional anesthetics. These differences include the following :
Ketamine, unlike traditional anesthetics
which cause total depression of the central
nervous system, affects selectively pain conduction and perception systems, stimulating
one area of the brain while simultaneously
depressing another ("dissociation") .
Ketamine stimulates the cardiovascular system while traditional anesthetics depress cardiovascular function.
Ketamine has antiarrhythmic properties while
traditional anesthetics do not. They may
even precipitate arrhythmias.

Use of ketamine predominantly in infants
and children up to 14 years of age.
The use of ketamine in adult patients is confined to surgical conditions for which ketamine has proven to be particularly advantageous, safe, and superior to conventional
anesthetic agents and methods ( see under 3).
Narcotic addicts and patients with a history
of chronic alcohol abuse or suffering from
acute alcohol intoxication are poor candidates for ketamine anesthesia because in
these patients even excessive doses of ketamine may fail to control body movements.

3. Limiting the use of ketamine anesthesia to
the following specific surgical areas and conditions:
Surgical treatment of burns*

Ketamine maintains or even exaggerates protective reflexes while traditional anesthetics
suppress them.
Ketamine ensures airway patency, provided
no mechanical airway obstruction is present,
while traditional anesthetics require additional tools and techniques.

Out-patient ophthalmology (tonometry, fundoscopy, gonioscopy).
Out-patient oral surgery (tooth extraction,
surgery on the gingiva).

Ketamine does not produce the traditional
"anesthetized" appearance in the patient, but
rather a characteristic "disconnected" appearance.

Out-patient otology ( myringotomy, insertion
of myringeal tubes, removal of foreign body
from ear canal) .

2. Knowledge of the criteria used for selection
of patients for ketamine anesthesia:

Out-patient plastic surgery (removal of nevi,
suturing of laceration, removal of scars).

* Presented at the 25th Annual Stoneburner Lecture
Series, February 25, 1972, at the Medical College of Virginia, Richmond .
MCV

Neurodiagnostic procedures such as pneumoencephalography, ventriculography, myelography, and carotid arteriography.
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* Patients of all ages may be included.
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Elective orthopedic surgery ( reduction of
congenital hip lu xation, spicacast application) .
Emergency orthopedic surgery ( closed redu ction of fr actures).
R epeated manipul ation und er anes thesia ( irradiation of inoperable int raoc ul a r o r intracra ni al les ions) .
Induction of anesthes ia in high-ri sk patients, including asthm atics, prior to the use
of the princi ple anest hetic. Ketamine-induced cardiovascular stimul ation and its relaxant effect on bronchi al mu scul ature offer
significa nt advantages over conventi onal anesthetic agent s. *
C ardiac cath eteri zation.
Open heart surgery, particul arly in volving
patients with minim al or no cardi ac reserve.
C ardiovascular stimul ati on and a ntiarrh ythmic affe cts of ketamin e offer prime advantages over traditional anesthetics.*
Emergency surge ry in pati ents suffering
from hypovolemia o r shock-lik e conditions.
Ketamine may be used fo r induction or to
enh ance minim al conventional anesthesia. It
offers the advant age of ensuring ca rdiovascul ar support until convention al measures to
control hypovolemi a a nd shock ca n be instituted and become effecti ve.*
Contraindications. Ketamine is contraindicated
with hypertension, histo ry of cerebrovasc ul ar accident , upper respirato ry infection, increased cerebrospinal fluid pressure, abdomin al surge ry, and oth er
surgery in volvin g vi sceral pain ( unless suppl emented
with conventio nal anesth etics).
Technique of Administration of Ketamine.
Pre-anesthetic medication: Infa nts and children
receive scopolamine 0.1 to 0.4 mg, depending o n age
and weight, given int ra mu scularly 1/2 to 1 hour prior
to surgery to counteract ketamin e-induced hypersalivati on. Pentobarbital or secobarbit al ( 0.5 to 1 mg
per pound) may be given fo r additio nal sedation.
Adult patients receive a tra nquilizer with antipsychotic properties, preferably d roperidol ( 1 to 2 ml)
or Inno var® ( 1 to 2 ml ) co mbin ed with 0.4 mg of
atropine administered int ramu scularly 1/2 to 1 hour

prior to surgery. Other combin ati ons of narcotic
analges ics, tranquilizers, and ataractics have proven
less effective as co mpared with the above-mentioned
medication.
Omitting n arcotics or barbitu ra tes in th e preanestheti c medicati on will signific antl y sho rten recovery time. No pre-anesth etic medi cati on is given to
patients undergo ing ambul atory surgery provided
that th e surgical proced ure is limited to 15 minutes.
Indu ction: W ith th e int ravenous route, th e initial
dose of ketamin e ranges fr om 1 to 2 mg per kg depending on the physical state of th e pati ent. It is
reco mmended th at ketamine be admini stered slowly,
over a peri od of 30 to 60 seconds. More rapid admini stration m ay result in respi ratory depress ion .
With th e intramu scul ar route, th e initial dose of
ketamine ra nges from 6 to 12 mg per kg.
Main tenance: Supplemental in crements of 1/ 2
to 1/ 3 of the full inductio n dose may be admini stered
intravenously every 8 to 10 minutes or intramuscularly every 20 to 30 minutes, or wh en movements of
head or extremities indi cate lightening of anesth esia.
Complications. The foll ow ing complications may
be encountered :
T emporary augmentation of pulse rate and
blood pressure beg innin g shortl y aft er injec tion of th e
dru g. This ca rdi ovasc ul ar-stimul ating effect of ketamine may prove benefi cial in cert ain circumstances,
for example, in th e presence of hypotension or shocklike states . In hypertensive individu als, however,
stimul ati o n may be considered undes irabl e or unsafe.
T ransient depression of respiration in res ponse
to ra pid intrave nous injection or in conn ection with
an ove rdose of ketamin e.
Paroxysmal coughing in the presence of upper
respi ratory infection, occurring immedi ately foll owing the initial injection of ketamine and recurring
with supplement al increments.
Vi vid dreaming, with or without psychomotor
acti vity, confusio n, and irrational behavior occurring
du ring emerge nce from anesth es ia. This complication
is more often obse rved in adults th an in children and
in fa nt s.
Tonic and clonic muscle movements resembling
convulsive seizures occurring in cert ain patient s without electroenceph alographic ev idence of seizure activity.
Eryth ema o r morbillifo rm rash occurrin g subsequ ent to th e initial inj ecti on of ketamine. The skin
erupt ion is transient and usually confi ned to face,
nec k, and upper chest.
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Treatment of Complications. Proper pre-anesthetic medication as outlined above may signficantly
suppress or even eliminate most adverse reactions.
This holds particularly true with regard to post-anesthetic emergence delirium reactions. The incidence
and degree of these psychic disturbances can be further minimized by avoiding premature verbal or
tactile stimulation of the patient ( "sensory deprivation") .
Post-anesthetic emergence delirium reactions,
should they occur in spite of proper pre-anesthetic
medication, may be successfully treated with intravenous droperidol-1 to 2 ml. Also recommended
are ultra short-acting barbiturates such as pentothal
or surital administered intravenously at doses of 75
to 100 mg.
Tonic and clonic movements during anesthesia
may be effectively treated with small intravenous
doses (2 to 5 mg) of diazepam (Valium®).
Ketamine does not provide adequate control of
pain originating from the viscera. Therefore, the
drug is not recommended for use as a sole anesthetic
in abdominal or thoracic surgery or where visceral
pain is expected to occur. In order to control visceral
pain, ketamine may be supplemented with other general anesthetic agents.
In summary, ketamine, a phencyclidine derivative, is a unique and unusually safe, effective
anesthetic agent. It is short-acting; it can be given
either intravenously or intramuscularly; it is rel atively easy to control, requiring little in the way
of adjunctive or supportive drugs or devices. It differs
markedly from previously established general anesthetics because of its selectivity with respect to the
central nervous system. Ketamine is capable of simultaneously depressing cortico-thalamic pathways and
activating limbic areas, referred to as "dissociation,"
and the resulting state is, therefore, termed " dissociative" anesthesia.
Profound analgesia is produced without concomitant respiratory depression and without inhibiting reflexes that protect the air passages. The
cardiovascular system is slightly stimulated.
Ketamine has proved to be of unique value in
the anesthetic management of patients, particularly
infants and children, undergoing a variety of surgical
and diagnostic procedures involving the head, neck,
and extremities and those necessitating frequent position changes such as are encountered in neurosurgical
diagnostic procedures and in the treatment of severely burned patients of any age.
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Properly administered and with due regard for
its specific advantages as well as its possible disadvantages, ketamine may prove superior to convention al anesthetic agents and methods in a variety of
specific surgical procedures.
INNOVAR . Innovar is a mixture of two drugs :
droperidol, a butyrophenone derivative, with strong
tranquilizing, antiemetic, and adrenergic-blocking
properties ; and fen/any/, a powerful narcotic analgesic
related to meperidine which differs from conventional narcotics by its high potency and its fast onset
and short duration of action. The two drugs are
mixed in a ratio of 50 to I. When administered intravenously in appropriate doses, a state of neuroleptanalgesia is produced in which the patient is
rendered immobile and insensitive to pain. His face
being expressionless, the patient appears detached
from his surroundings, yet he remains alert and cooperative. Respiratory function is depressed and it
may be necessary to assist or control the respiration
via a face mask or endotracheal tube. If nitrous
oxide-oxygen mixtures are added to produce sleep
and memory deficit, the state of neuroleptanesthesia
is established.
Innovar or its separate component drugs, droperidol and fentanyl , can and will provide optimal
conditions for the patient and surgeon provided
that certain basic principles and rules are observed
along with the use of the drugs which may be listed
as follows:
1. Adherence to minute details with regard to
the technique of administering the neuroleptanalgesic drugs.
2. Employing neuroleptanalgesia and anesthesia preferably in poor-risk, debilitated, or
geriatric patients undergoing major, traumatic, and prolonged surgery, and avoiding
their use in pediatric surgery and in shortlasting, uncomplicated, and minor surgery.
Technique of Administration of Innovar or Its
Separate Components, Droperidol and Fentanyl, to
Produce Neuroleptanalgesia.
Pre-anesthetic medication: Droperidol alone
(2.5 to IO mg, depending on age and physical state)
or Innovar (1 to 2 ml) is given intramuscularly 30
to 60 minutes prior to surgery. Atropine or scopolamine (0.4 to 0.6 mg i.m.) may be added to control secretions.
Induction using Innovar: The recommended
dose of Innovar is 1.0 ml per 25 pounds of body
weight. This may be reduced to 0.5 ml per 25 pounds

88
of body weight in extremely poor-ri sk and debilitated
patients. Individu als in good physical state may receive 1.5 to 2.0 ml per 25 pounds of body weight.
In a patient of average weight th e tot al ca lculated
dose of Innovar ranges from 6 to 8 ml. D ebilitated
and reduced pati ents may receive 5, 4 , or 3 ml ,
while patient s in a satisfacto ry physical state m ay
receive 9 or 10 ml. Th e total dose of lnnova r will
rarely exceed 10 ml.
A test dose of I to 2 ml of Innov a r inj ected
intravenously over a period of 1 minute is always
used prior to the administration of the full calcul ated
dose. One to two minutes following th e inj ection of
the test dose, the bl ood pressure is recorded , a nd if
unch anged, th e remaind er of th e dose is administered. A blood pressure drop of more th a n 25 mm
Hg in response to the intravenou s test dose
usually indicates in adequate circulatory volume requiring rapid intra venous infusion of 500 to 1,000 mm
of fluids before proce eding with furth er administration of Innov ar.
Th e compounded tot al dose of lnn ova r m ay b e
administered as follows:
a. Intra venous drip: The solution to be infused
should cont ain 10 ml of Inn ovar added to
250 ml of 5 % dex trose in water or saline.
This mi xture is administered by th e microdrip techniqu e at the rate of 150 to 200
drops per minute. Wh en incre ased somnolence and psychic detachment are noticeable
-usuall y within 3 to 5 minutes after start
of th e infusion-a local anesthetic ( cocaine
5 % , lidoca in e 4 % ) is topically appli ed
eith er by intralaryngeal spray or by inj ection
through the crico-thyroid membrane. Wh en
th e pati ent's respiratory rate has slowed to
10 per minute, th e intraveno us drip is slowed
to 100 drops per minut e. At thi s point ,
psychic indifference is further enhanced, and
analges ia has usu ally reac hed th e optim al
level. The int ra venous drip is th en disco ntinued and the patient is ready for the
surgic al procedure while still responding to
commands such as "take a deep bre ath " or
"open your mouth. "
b. Intra venous injection: The calculated dose of
Innovar is injected intravenou sly in increments of 1.0 to 2.0 ml over a period of two
to three minut es.
Maintenance: In order to hold th e leve l of surgical ana lgesia, fentanyl in doses of 0.05 to 0.1 mg ( 1
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to 2 ml) is administered intravenou sly when ch anges
in vit al signs such as increased hea rt rate, elevated
bl ood pressure, increased respiratory rate, or irregul ar breathing indic ate lowerin g o f the p ain threshold. It is not recomm ended th at Jn novar be administered fo r m aint enance of surgica l analges ia because
of poss ible cu mul ative effects of th e lon ger-acting
droperidol which may res ult in over-tranquilization
postoperatively.
Postoperative period: Usually, analges ia extends
well into the postoperative peri od . Therefore, patients rarely require narcotic a nalges ics for pain relief. If narcotic analgesics a re admin istered , their
dose should be reduced to 114 or 1/ 3 of the usually
recommended dose.
Induction using droperidol and fentanyl as
separate drugs: Inducti on is started with the intravenou s administrat ion of droperidol (0 .15 mg per
kg). The patient 's vital signs are obse rved for 5 to 6
minutes and if no change is noted, an initial dose of
20 to 60 mcg of fentan yl is administered intravenously followed by 20 to 40 mcg doses of fentanyl ,
give n at about two-minute intervals at which time
the patient is considered ready for the operative procedure.
Indications. Neuroleptanalgesia should be limited to p ati ents in whom retention of consciousness
a nd cooperation durin g th e surgica l procedure is
desired. Such procedures includ e: bronchoscopy,
laryn goscopy. and esophagoscopy; neurodiag nostic
procedures such as pn eum oe nceph alography and
carotid arteriogra ph y; cardiac cath eteri za ti on ; stereotactic procedures includin g cryoth alamotomy; resecti o n of epileptogenic focus; ophthalmic surge ry ( in
conjunction with regiona l anesth esia); middl e and
inner ear surgery ( in conjunction with local anesthesia); and oral surgery includin g tooth ex traction
a nd other intrao ral surgical procedures involving the
gin giva and th e to ngue.
Contraindications. Neuroleptanalgesia is contraindicated for ambulatory surgery , surge ry in infants and chi ldren, acute alcohol delirium or history
of alcoholism , and narcotic addicts.

Technique of Administration of lnnovar or Its
Separate Components, Droperidol and Fentanyl, to
Produce Neuroleptanesthesia.
Pre-anesthetic m edicatio n: This is the same as
th at described unde r neurol eptanalgesia as is the
compositi o n of the total dose to be administered for
producing the neurolept anesthetic state.
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Ind11ction: Inn ovar may be admini ste red as fo llows:
a. Intra venous drip: Prepara ti on of th e so lut ion
to be infused a nd indu ctio n are id e nti ca l with
the meth od desc ribed unde r neurole ptana /gesia. A t
the time th e patient shows signs of so mn ole nce
and obtunda tion in response to th e infusion, th e
intrave nous d rip is slowed to I 00 d rops pe r minut e
and continued at thi s rate thro ughout th e anesthesia course. Ad ministration of nit rous ox id e-oxyge n ( 4: 2 ) by face mask is begun , a nd th e pa ti ent is
encou raged to take dee p breath s. Within o ne minut e
the pati ent usuall y lapses into unco nscio usness without excitement. An int rave nous dose o f short- ac ting
muscle rela xant is administered to fa c ilitate e ndotrach eal intubati on and to co unt eract musc le rigidit y
which may develo p during this ph ase. As a rule , th e
patient resumes spont aneo us brea thing within fi ve to
eight minut es. D-tubocu ra rin e is ad mini ste red intravenously at conventio nal dosages if muscle relaxa ti on
is needed fo r surge ry. Wh en ch anges in vit a l signs
indicate lightenin g of a nes th es ia, th e dri p rate is increased until vital signs return to norm al.
b. Intra veno us injection: Simil a r to th e meth od
of neurol ept analges ia, a tes t dose of I to 2 ml o f
Innova r is admini stered intrave nously ove r a peri od
of I minute. Blood pressure is reco rded subsequ ent to
this inj ection and , if fo und esse ntiall y unch a nged ,
furth er increments of I to 2 ml of Innovar are administered intra veno usly at 1- to 2-minute intervals.
By the time th e to tal calcul ated dose has been administered , th e patie nt sho ws signs of drows in ess and increasing tranquili za ti on. While th e pati ent still is able
to res pond to questi oning, th e brea thing mask is
applied and nit rous ox ide-oxyge n, a t th e fl ow of 4
liters of nitrous ox ide and 2 lit ers of oxyge n per
minute, is admini stered. While spo nt a neous breathin g
is increasingl y more depressed , positi ve press ure
ventil ation via the fa ce mask is begun with th e pati ent
responding to th e comm and to take deep breaths. A s
a rule, aft er 5 to 8 breath s the patient lapses into unconsciousne ss with out excitement. Imm edi ately prior
to the loss of co nscio usness, an intrave nous dose of a
snort- actin g muscle relax a nt is admini ste red to fac ilitate endotrach eal intub ati o n a nd avoid th e develo pment o f fentanyl-induced muscle rigidity.
Maintenance: F o r maintenance o f th e neuroleptanesth etic state, administrati on o f nit rous oxid eoxygen ( 4 : 2) is co ntinued. F ent anyl is admini stered
intravenou sly at doses to l to 2 ml (0.05 to 0 . 1 mg )
when ch anges in vit al signs ( increased hea rt rate,
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elevated blood press ure, inc reased respiratory rate,
or irregul a r brea thing ) indi cate lowe rin g of th e pain
threshold . Th e res ponse to th e administration of
fe nt a nyl is us uall y p ro m pt, and signs of in adequ ate
pa in th reshold elevation disa ppea r within 45 to 60
seco nd s. If th e vital sign s co ntinu e to indicate insuffic ient analges ia, a no th er in crement of I to 2 ml of
fent anyl is admini stered intravenously. In an average pati ent , admini stratio n of suppl emental intraveno us fe nt a nyl doses is required at 45 to 60 minute
int erva ls. F enta nyl for ma inte nance of an es thesia may
also be given intra mu scularl y at th e sa me dose as
me nti o ned above. Adequ ate pain threshold elevati o n usuall y is accompli shed with thi s route of admini strati on within 7 to 8 minutes a nd may last up to
2 hours.
In abd ominal surgery or oth er procedures requiring mu scle relaxati on, d-tubocurarin e may be admini ste red a t conve nti onal intrave no us doses .
E m ergence: Return to consciousness is rapid , as
soon as th e administrati on of nit rous oxide-oxyge n is
di scontinued . Within 3 to 5 minut es th e patient is
usuall y in co nt act a nd ca n answer qu estions. If respiratory exc hange is in adequ ate, the endotracheal tube
may be left in pl ace in orde r to mech anically suppo rt
ventil atio n until sati sfactory respiratory function is
rees tablished, at which tim e th e endotrachea l tube is
removed. Levall orph an ( Lorfa n®) may also be given
at int rave nous doses of I mg to counteract fentanylinduced res piratory depress ion. If Lo rfa n fail s to resto re adequ ate res piratory functi o n, other factors
ca using respi ratory depress ion sho uld be examin ed.
Compl ete analges ia usually is maint ain ed for 4
to 6 hours. Nausea and vomiting are rarely encountered.
Indications. Ne urol ept a nesth es ia is indicated for
the foll ow in g: bili ary surge ry for whi ch haloge nated
a nesthetic s may be co ntraindic ated; ma jor, trauma tic, prolonged surgery involving poo r-ri sk patients;
neurosurge ry; cardi ovascu lar surge ry includ ing open
hea rt procedures ; surge ry for orga n transpl ant ation,
particul arly kidn ey transpl ant s; middl e and inner ea r
surgery ; and eme rge ncy surgery involving elderl y,
debilitated, and reduced patients; a nd pati ents in
shock-like states.
Contraindications. T he co nt ra indi cations for
neurole pt anesthes ia a re the sa me as those under
neuroleptanalgesia. In addition, th e use of Innova r
may be co ntraindica ted in asthm atic patients since
it may precipitate a n att ack.
Complications. H ypotension is most commonly
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encountered during induction of neurolepta nes th esia,
indicat in g in adequ ate circulatory volume and in ability of the patient to compensa te for periphera l vasodilatation caused by droperidol-induced alph a-adrenergic blockade. Treatment should consist of rapid
infusion of 500 to 1,000 ml of lactated Ringer's solution or 5 % dextrose in water solution in prefe rence
of th e use of vasopressors.
Excessive blood pressure elevation, th e etiology
of which is und etermined , has occ urred in rare instances. Int ermittent admini stration o f halothane at
conventional concentration s or small int ravenou s
doses of chlorprom azine (7.5 to 15 mg i.v.) have
proved to be effec tive in restoring accept able blood
press m e leve ls.
D roperidol may induce extrapyramidal muscle
acltv// y which may be controlled with antiPa rkinson age nts such as Coge ntin®.
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